Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02832063 · ClinicalTrials.gov registry record · Phase 2
Clinical Trial in Subjects With Mild to Moderate Acne Vulgaris
A Phase 2 study of Acne Vulgaris, sponsored by AOBiome.
- Completed
- Registry status
- Phase 2
- Development phase
- 372
- Enrollment target
- 1
- Study location
NCT02832063 is a Phase 2 study of Acne Vulgaris that has completed, run by AOBiome. The registered enrollment target is 372 participants, above the 270-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (38% higher). The trial reports 1 study location across 1 state.
The verdict
NCT02832063, a Phase 2 study of Acne Vulgaris, has completed, sponsored by AOBiome.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 372 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to demonstrate the safety, tolerability and efficacy of B244 administered over 12 weeks to participants with mild to moderate acne vulgaris relative to placebo.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL B244
Study Locations (1)
California
- Science37 - Culver City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 372 participants |
| Start Date | 2016-08 |
| Est. Completion | 2017-07-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02832063
The ClinicalTrials.gov registry entry for NCT02832063 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 372 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 270-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (38% higher). The listed sponsor is AOBiome, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acne Vulgaris appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02832063 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02832063 about?
NCT02832063 is a clinical study titled "Clinical Trial in Subjects With Mild to Moderate Acne Vulgaris". The purpose of this study is to demonstrate the safety, tolerability and efficacy of B244 administered over 12 weeks to participants with mild to moderate acne vulgaris relative to placebo.
What is the current status of trial NCT02832063?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 372 participants. The study started on 2016-08. Estimated completion is 2017-07-19.
What conditions does trial NCT02832063 study?
This clinical trial studies the following conditions: Acne Vulgaris.
What interventions are being tested in trial NCT02832063?
The interventions under investigation include: Placebo (BIOLOGICAL), B244 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02832063?
This trial is sponsored by AOBiome, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02832063 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acne Vulgaris
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults
ACTIVE NOT RECRUITING · Phase 2
-
Dose Range Study of CD5789 in Acne Vulgaris
COMPLETED · Phase 2
-
An Evaluation of the Adrenal Suppression Potential and PK of CB-03-01 Cream in Pediatric Patients With Acne Vulgaris
COMPLETED · Phase 2
-
Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Patients With Skin Type V or IV With Acne Vulgaris
COMPLETED · Phase 2
-
Efficacy and Safety Study of Gevokizumab to Treat Moderate to Severe Acne Vulgaris
COMPLETED · Phase 2
-
A Clinical Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.